NCT06405945Recruiting
Cervical Cancer Susceptible Population Classification
Evalutaion of the SNPs Test in Average Cervical Cancer Screening Episode
Source: ClinicalTrials.gov · Last updated 9 May 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Cervical cancer is the third most common lethal tumor globally, causing around a quarter million deaths annually, despite the availability of HPV vaccines. Recent Genome-wide association studies (GWAS) have identified numerous genetic markers linked to cervical cancer, including rs10175462, rs10007915, rs35721900, and rs61646675, which have been verified as being related to susceptibility to cervical cancer. However, many reports lack clarity, consistency, and validation. In this comprehensive study, we will analyze the genomic risk factors associated with cervical cancer, classify individuals into different risk categories, and explore potential biomarkers and therapeutics.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 10000 (estimated)
- First submitted
- 5 May 2024
- Start date
- 1 May 2024
- Primary completion date
- 30 Apr 2034
- Lead sponsor
- Anhui Provincial Hospital
- Diseases
- Cervical cancer
- NCT number
- NCT06405945
What you commit to
- Study type: Observational
- Planned participants: 10000
- From 1 May 2024 to the primary completion date, 30 Apr 2034
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of any malignancy (patients who have undergone surgical removal of skin squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of informed consent for the study)
- Currently taking any anti-neoplastic or disease-modifying anti-rheumatic drugs.
- Any major physical trauma (e.g. disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent
Other illness
- History of cervical cancer
- Known medical condition which, in the opinion of the investigator, should preclude enrollment into the study
Who the study is looking for
- Subjects aged \>=18 years at time of consent
- Intended to undergo screening colposcopy
- Considered by a physician or healthcare provider as being of "average risk" for cervical cancer
- Willing to consent to blood draw cervical disease treatments
- Willing to sonsent to follow-up for five years as per protocol
Age in the registry: 18 years to - · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of USTC Coordinator of this site? Confirm its status | Hefei | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.